SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.

A SPAC III Acquisition Corp. - Ordinary Shares - Class A

Alpha Capital Acquisition Co - Ordinary Shares - Class A

Alpha Capital Acquisition Co (ASPC) is experiencing significant market attention, fueled by its extremely low share float and a reported high short interest. The trading community is actively discussing a potential short squeeze and anticipating substantial upward price movement, frequently drawing parallels to other recent volatile low-float SPAC runners. However, some market participants advise caution, referencing the stock's historical tendency for rapid gains followed by sell-offs.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is trending after its experimental depression treatment, BHV-7000, failed to meet its primary endpoint in a Phase 2 study, leading the company to halt further psychiatric trials for the drug. Despite the setback, which analysts widely deemed "disappointing but not surprising," community focus is now strongly shifting to the company's broader pipeline, especially upcoming pivotal data for its epilepsy program and other key immunology and obesity assets.

Coeur Mining, Inc. engages in the well-diversified, growing precious metals producer with a focus on generating sustainable, high-quality cash flow and returns from a balanced, prospective asset base in mining-friendly jurisdictions along with commitment to exploration and expansions. It operates through the following segments: Palmarejo, Rochester, Kensington, Wharf and Silvertip. The Palmarejo segment includes a gold-silver complex. The Rochester segment operates an open pit heap leach silver-gold mine in northwestern Nevada. The Kensington segment relates to an underground gold mine located north of Juneau, Alaska. The Wharf segment focuses on an open pit heap leach gold mine located near Lead, South Dakota. The Silvertip segment silver-zinc-lead exploration located in the state of Sonora in northern Mexico. The company was founded in 1928 and is headquartered in Chicago, IL.

Coeur Mining Inc

Coeur Mining Inc. is a key discussion point following its strategic $7 billion acquisition of New Gold, positioning it as a major North American precious metals producer amidst a strong bull market for gold and silver. The community is actively discussing CDE's robust Q3 earnings and silver's record highs, with many anticipating significant upside as institutional interest grows in the mining sector.

Coupang, Inc. engages in the provision of retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, and Farfetch. It operates through the Product Commerce and Developing Offerings segments. The Product Commerce segment consists of the company's core retail and marketplace offerings and Rocket Fresh, its fresh grocery category offering. It also includes advertising products associated with these offerings. The Developing Offerings segment covers the company's more nascent offerings and services including: Coupang Eats, a restaurant ordering and delivery service in Korea, Coupang Play, an online content streaming service in Korea, fintech services, retail operations in Taiwan, as well as advertising products associated with these offerings. It also includes Farfetch, a global luxury fashion marketplace. The company was founded by Bom Kim in 2010 and is headquartered in Seattle, WA.

Coupang Inc - Ordinary Shares - Class A

Coupang Inc 

Coupang is facing intense scrutiny and widespread community backlash following a massive data breach affecting millions of users, with discussions heavily focused on the company's response and its CEO's perceived lack of accountability in South Korea. This has triggered calls for boycotts and potential multi-billion dollar lawsuits, even as some investors eye the stock as an oversold opportunity, weighing its market dominance against significant regulatory and consumer trust challenges.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Petroleo Brasileiro is trending due to rapidly escalating geopolitical tensions in the Middle East, which are propelling oil prices higher and intensifying market interest in energy producers. The community is actively discussing PBR's unique position as an undervalued oil major operating in a non-conflict region, prompting expectations for strong performance and continued attractive dividends.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is generating considerable excitement due to multiple impending FDA decisions, including Tradipitant for motion sickness and GLP-1 induced nausea, Hetlioz for jet lag following a successful court appeal, and Bysanti for psychiatric disorders. The community is actively discussing the substantial revenue potential from these pipeline catalysts, particularly Tradipitant's entry into the massive GLP-1 market, viewing the stock as significantly undervalued. This confluence of regulatory events and a strong pipeline fuels bullish sentiment, with many anticipating significant upside potential and the possibility of renewed buyout interest.

ProShares Trust - ProShares UltraShort Silver -2x Shares

ProShares UltraShort Silver

ProShares UltraShort Silver ($ZSL) is trending as the community hotly debates the sustainability of silver's recent rally, with many anticipating a significant pullback for the metal. Traders are actively initiating or adding to short positions, betting that silver is overbought and due for a correction, citing the historical tendency of parabolic moves to reverse. However, some caution against shorting precious metals in the current macro environment, highlighting the inherent risks and historical underperformance of inverse leveraged ETFs over time.

Memecoin on Injective taken over by the community.

Nonja

NONJA is a top trending memecoin within the Injective ecosystem, actively discussed for its strong community and robust fundamentals, including high burned liquidity and an unruggable structure. Community members are accumulating, viewing $NONJA as a high-leverage opportunity tied to Injective's recent EVM mainnet launch and ongoing ecosystem growth, expecting significant upside as the chain matures.

OpGen, Inc. is a precision medicine company, which engages in the power of molecular diagnostics and informatics to help combat infectious disease. It focuses on the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Clarksburg, MD.

Opgen Inc

Opgen Inc. (OPGN OTC) is seeing significant community discussion as investors react to recent corporate filings, including the extension of a key stock purchase agreement, bolstering hopes for the company's strategic pivot. The community is eagerly anticipating a potential Nasdaq relisting and the full launch of its AI-driven CapForce fintech platform, driving speculative conversations around a major turnaround and future valuation.

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals is trending as analysts largely dismiss negative read-throughs from a peer's recent depression study miss, reinforcing confidence in XENE's differentiated Kv7 program. The community is actively discussing XENE's positive thesis remaining intact, particularly its lead asset azetukalner showing promise in both focal epilepsy and major depressive disorder. With key Phase 3 epilepsy data anticipated in early 2026 and a robust pipeline, investors are closely watching the company's advancing neurological and neuropsychiatric programs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
